Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma.

Related Articles

Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma.

Oncotarget. 2016 Oct 11;:

Authors: Zhou N, Liu CM, Hou HL, Zhang CT, Liu D, Wang GQ, Liu KW, Zhu JJ, Lv HY, Li TJ, Zhang X

Abstract
Spindle cell carcinoma of the breast is a rare subtype of metaplastic carcinoma, and no effective chemotherapy special for metaplastic carcinoma exists until now. As spindle cell carcinomas of the breast are typically "Triple Negative", endocrine therapy and molecular therapy targeted to Her2 might not be favorable, resulting in poor prognosis. Apatinib is currently being tested in patients with breast or lung cancers. Here we report a successful case using Apatinib to treat spindle cell carcinoma of breast.A 52- year- old woman presented with a gradually enlarged lump in left breast, which was revealed to be a triple-negative spindle cell carcinoma, underwent a modified radical mastectomy. After the first line chemotherapy with Cyclophosphamide and Epirubicin, multiple metastases in bilateral lung and left anterior thoracic wall appeared. After disease progressed with therapy of Bevacizumab combined with Albumin-bound Paclitaxel and Cisplatin, we treated the patient with Apatinib according to her VEGFR expression, which showed nearly complete response and controllable and tolerated side effects. Next-generation sequencing analysis of the tumor specimen and real time ctDNA was performed to observe the mutated gene numbers matched with therapeutic effect. The present case can help to provide a new and effective therapy strategy to treat advanced spindle cell carcinoma.

PMID: 27738308 [PubMed - as supplied by publisher]

http://ift.tt/2e90i4L


http://ift.tt/2e8aUmg


http://ift.tt/2e8Z0a2